MarketBeat
30 Jul 2026, 23:04 UTC · 11w ago
Fulgent Genetics Q2 Earnings Call Highlights
Impact · against what's priced in
Fulgent Genetics faces immediate downward pressure as it lowers full-year revenue guidance to $330M–$340M. The combination of a major customer shifting testing in-house and operational failures in its new billing system creates a structural and execution-based headwind that outweighs the inorganic growth from Bako and StrataDx.
- FLGT−0.60
No priced-in read yet
- In context
The company lowered 2026 revenue guidance to $330M–$340M due to a major customer moving testing in-house and billing system errors that compressed GAAP gross margins to 30.1%. While Bako and StrataDx provide growth, they only partially offset the loss of the largest client and operational inefficiencies.
